Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.69 |
| ▸ | MAPT | P10636 | 2/20 | 0.69 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | VDR | P11473 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5528619 | 0.83 | MEN1 (0.73) | MEN1KMT2AMAPTGAAPOLB | |
| SCHEMBL9694491 | 0.82 | MEN1 (1.00) | MEN1KMT2AMAPTGAAPOLB | |
| SCHEMBL29367470 | 0.81 | KMT2A (0.74) | MEN1KMT2AMAPTGAAPOLB | |
| SCHEMBL6524461 | 0.81 | KMT2A (0.74) | MEN1KMT2AMAPTGAAPOLB | |
| SCHEMBL5525817 | 0.79 | MEN1 (0.67) | MEN1KMT2AMAPTGAAPOLB | |
| SCHEMBL26497888 | 0.79 | KMT2A (0.71) | MEN1KMT2AMAPTGAAPOLB | |
| SCHEMBL9671323 | 0.79 | MEN1 (0.71) | MEN1KMT2AMAPTGAAPOLB | |
| SCHEMBL9396061 | 0.79 | KMT2A (0.71) | MEN1KMT2AMAPTGAAPOLB | |
| SCHEMBL10914237 | 0.79 | MEN1 (0.76) | MEN1KMT2AMAPTGAAPOLB | |
| SCHEMBL26497891 | 0.78 | MEN1 (0.65) | MEN1KMT2AMAPTGAAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070275935-A1 | Estratriene Derivatives | CRYPTOPHARMA PTY LTD (AU) | 2007-11-29 | — | — | US | disclosed |
| EP-1625143-A1 | ESTRATRIENE DERIVATIVES | Cryptopharma Pty Ltd (AU) | 2006-02-15 | — | — | EP | disclosed |
| WO-2004101595-A1 | ESTRATRIENE DERIVATIVES | CRYPTOPHARMA PTY LTD (AU) | 2004-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275935-A1 | Estratriene Derivatives | ESR2, ESRRB, NR3C2 | MEN1 2306/4885KMT2A 1076/4885MAPT 4065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.